Dr Rahul Bhargava

Non-Hodgkin Lymphoma Treatment Cost in India

Book a Consultation Call
Non-Hodgkin Lymphoma Treatment Cost in India
Treatment Cost
$3,600 to $30,000
Stay in India
4 to 6 weeks
Success Rate
60 to 90%

Non-Hodgkin lymphoma (NHL) is a subtype of blood cancer that starts in the lymphatic system. With early diagnosis and appropriate treatment, many forms of NHL are manageable and even curable. India has emerged as a leading destination for effective and affordable treatment of non-Hodgkin lymphoma, attracting patients from across Europe, Africa, the Middle East, and Southeast Asia.

The cost of non-Hodgkin lymphoma treatment in India typically ranges from ₹3,00,000 to ₹25,00,000 (approximately $3,600 to $30,000), depending on the type and stage of the disease, treatment methods used, and hospital facilities. This is significantly lower than treatment costs in Western countries, often offering savings of up to 80% while maintaining global standards of care.

 

Book a Consultation Call

What is Non-Hodgkin Lymphoma?

Non-Hodgkin lymphoma (NHL) is a type of blood cancer that originates in the lymphatic system, a crucial component of the body's immune defense. It occurs when WBCs called lymphocytes grow abnormally and form tumors throughout the body. Unlike Hodgkin lymphoma, NHL does not involve the presence of Reed-Sternberg cells, a specific type of abnormal cell found only in Hodgkin lymphoma.

There are over sixty subtypes of Non-Hodgkin lymphoma, which are classified into two main categories:

  • B-cell lymphoma which accounts for about 85–90% of NHL cases.
  • T-cell lymphoma, which is less common, may behave more aggressively.

Some types of NHL are slow-growing (indolent), while others are fast-growing (aggressive). Common types include diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, and peripheral T-cell lymphoma. The course of the disease and treatment approach vary depending on the type and stage of NHL.

What are the Symptoms of Non-Hodgkin's Lymphoma?

Non-Hodgkin lymphoma symptoms often resemble those of common infections, which can delay diagnosis if not correctly evaluated. Swollen lymph nodes cause some symptoms, while others are related to how the disease affects organs such as the spleen, liver, or bone marrow.

Common symptoms include:

  • Painless swelling of lymph nodes in the neck, armpit, or groin is often the earliest and most noticeable sign.
  • Persistent fatigue and weakness are common due to the body's immune response and potential impact on red blood cell levels.
  • Unexplained weight loss, often exceeding 10% of body weight within a short period, maybe a significant concern.
  • A fever that comes and goes without any obvious infection can signal underlying lymphoma activity.
  • Night sweats that soak the sheets may occur even in a cool room and are a hallmark symptom of aggressive NHL.
  • Loss of appetite or feeling full quickly may happen when the spleen becomes enlarged.
  • Itchy skin or skin rashes may develop in some cases, especially with T-cell lymphomas.
  • Chest pain, cough, or shortness of breath can occur if lymph nodes in the chest area are enlarged.

If these symptoms persist for more than a few weeks or are unexplained by other conditions, a thorough medical evaluation is strongly recommended.

How is Non-Hodgkin's Lymphoma Treated in India?

India offers world-class treatment for non-Hodgkin's lymphoma, combining advanced technologies, experienced oncologists, and globally recognized treatment protocols. International patients benefit from world-class oncology hospitals equipped to handle chemotherapy, radiation therapy, and stem cell transplantation.

The treatment approach for non-Hodgkin's lymphoma in India depends on several factors, such as the specific subtype, stage, and aggressiveness of the disease, as well as the patient's age, overall health, and medical history. The goal of the treatment is to eliminate cancer cells, prevent relapse, and improve long-term survival.

Commonly used treatment modalities in India include:

  • Chemotherapy is the mainstay of treatment for most types of NHL. Indian hospitals utilize internationally approved regimens, such as CHOP, R-CHOP, or EPOCH, often in combination with monoclonal antibodies.
  • Targeted therapy involves the use of drugs like rituximab, which specifically target cancerous B-cells without affecting healthy cells. Targeted therapy is especially effective in B-cell lymphomas.
  • Immunotherapy helps the patient's immune system recognize and destroy lymphoma cells using advanced agents such as checkpoint inhibitors or monoclonal antibodies.
  • Radiation therapy may be used in early-stage disease or to shrink tumors in specific areas of the body. It's often combined with chemotherapy for improved outcomes.
  • Stem cell transplant (autologous or allogeneic) is considered for aggressive or relapsed NHL. Many top Indian hospitals offer both types of transplants at significantly reduced costs.
  • CAR T-cell therapy is a promising option for relapsed or refractory non-Hodgkin lymphoma, particularly in select private centers in India. Although costly, it remains more affordable compared to the West.

What is the Treatment Protocol for Non-Hodgkin's Lymphoma?

The treatment protocol for non-Hodgkin's lymphoma follows a structured sequence aimed at achieving remission, preventing relapse, and maintaining quality of life. While protocols vary slightly depending on the subtype and severity, most patients go through a combination of induction, consolidation, and maintenance phases.

Typical treatment protocol includes:

  • The initial diagnostic workup typically includes blood tests, imaging studies (such as CT or PET scans), a bone marrow biopsy, and sometimes molecular testing to determine the exact subtype.
  • Induction therapy begins with chemotherapy and/or targeted therapy such as the R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), given every 21 days for 6–8 cycles.
  • For aggressive types or high-risk patients, dose-adjusted regimens, such as DA-EPOCH-R, may be used to increase efficacy.
  • Oncologists may add radiation therapy for localized disease or bulky tumors after chemotherapy.
  • Patients who do not achieve complete remission or relapse after initial therapy may undergo autologous stem cell transplant. In high-risk cases, an allogeneic transplant may be advised.
  • For relapsed/refractory cases, second-line regimens (like ICE, DHAP, or GDP) followed by transplant or CAR T-cell therapy are considered.
  • Maintenance therapy using rituximab or lenalidomide is prescribed in select cases to prolong remission, especially in indolent lymphomas.
  • Regular follow-up is conducted every 3–6 months, including blood tests, imaging, and physical exams, to monitor for recurrence and manage late effects.

This structured, evidence-based approach ensures optimal outcomes while minimizing unnecessary side effects. Top Indian oncologists, such as Dr. Rahul Bhargava, follow NCCN and ESMO guidelines, ensuring consistency with global standards of care.

What is the Cost of Non-Hodgkin's Lymphoma Treatment in India?

India is globally recognized for providing high-quality cancer care at a fraction of the cost charged in countries such as the United States, the UK, or the UAE. Non-Hodgkin lymphoma (NHL) treatment in India is not only affordable but also follows international protocols and utilizes the latest medical technologies.

Most patients with non-Hodgkin's lymphoma can expect an overall treatment cost between ₹6,00,000 and ₹30,00,000 (approximately $7,200 to $36,000) depending on the treatment path and medical complexity.

This cost includes high-quality medical services, internationally trained doctors, and access to advanced treatments, making India a top choice for international cancer care.

Below is a general cost breakdown for various components of NHL treatment in India:

  • Chemotherapy (complete cycle): ₹3,00,000 to ₹8,00,000 ($3,600 to $9,600) depending on the number of cycles, drug combinations, and patient condition.
  • Targeted Therapy (e.g., Rituximab, Obinutuzumab): ₹1,20,000 to ₹2,50,000 per dose ($1,450 to $3,000). Multiple doses may be required, which can significantly impact the total cost.
  • Radiation Therapy: ₹2,00,000 to ₹5,00,000 ($2,400 to $6,000) for a full course, depending on the site, number of sessions, and technology used (e.g., IMRT, 3D-CRT).
  • Autologous Stem Cell Transplant: ₹12,00,000 to ₹20,00,000 ($15,000 to $25,000), including pre-transplant preparation, conditioning chemotherapy, hospital stay, and post-transplant care.
  • Allogeneic Stem Cell Transplant: ₹18,00,000 to ₹30,00,000 ($25,000 to $35,000), generally used in advanced or relapsed cases requiring donor stem cells.
  • CAR T-Cell Therapy (available in select centers): ₹45,00,000 to ₹55,00,000 ($40,000 to $60,000), still significantly lower than the $400,000+ cost in the US.
  • Supportive care and diagnostics (PET-CT, biopsies, lab tests, blood transfusions, anti-infective meds): ₹1,00,000 to ₹3,00,000 ($1,200 to $3,600) over the course of treatment.

Cost Comparison: Non-Hodgkin's Lymphoma Treatment in India vs Other Countries

One of the most compelling reasons patients travel to India for NHL treatment is the remarkable cost savings. Here is a comparative table showing the average cost range for complete NHL treatment across different countries:

Country

Chemotherapy + Targeted Therapy

Stem Cell Transplant (Autologous)

CAR T-Cell Therapy

India

$7,000 – $15,000

$15,000 – $25,000

$40,000 – $60,000

USA

$60,000 – $120,000

$100,000 – $200,000

$400,000 – $500,000

UK

$45,000 – $90,000

$80,000 – $160,000

Not widely available privately

UAE

$35,000 – $70,000

$60,000 – $120,000

$250,000 – $400,000

Thailand

$20,000 – $30,000

$35,000 – $50,000

Not routinely offered

South Africa

$25,000 – $45,000

$50,000 – $70,000

Limited availability

International patients visiting India can save up to 80–90% on total treatment costs, even when factoring in travel, accommodation, and post-treatment care. More importantly, they receive world-class care with access to advanced therapies, such as immunotherapy and stem cell transplants.

What are the Factors Affecting the Cost of Non-Hodgkin's Lymphoma Treatment in India?

The total cost of treating non-Hodgkin lymphoma (NHL) in India varies widely based on several medical, logistical, and personal factors. Understanding these factors helps patients and caregivers plan finances, select the right hospital, and prepare for the duration of treatment.

  • Type and Subtype of Lymphoma: Some forms of NHL, such as indolent (slow-growing) lymphomas, may require only observation or limited treatment. Others, like diffuse large B-cell lymphoma (DLBCL) or peripheral T-cell lymphoma, are aggressive and require more intensive, prolonged, and costly therapies.
  • Stage of the Disease at Diagnosis: Advanced-stage disease (stages III or IV) typically requires longer treatment durations, more chemotherapy cycles, or additional interventions, such as stem cell transplant, thereby increasing the total cost.
  • Type of Treatment Chosen: The type of treatment chosen has a significant impact on the cost.
    • Chemotherapy is more affordable than targeted or immunotherapy.
    • Targeted drugs (like rituximab) are expensive, especially if imported.
    • Stem cell transplant and CAR T-cell therapy are among the costliest components.
  • Number of Treatment Cycles and Hospitalization: More cycles of chemotherapy or immunotherapy result in higher drug and hospital-related expenses. Patients with complications may require extended ICU stays or additional supportive care.
  • Choice of Hospital and Location: Tertiary care hospitals in tier 1 cities, such as Delhi, Mumbai, and Bangalore, may charge more due to their advanced infrastructure. However, they often offer more specialized services, like transplant or immunotherapy, which may be necessary for complex cases.
  • Use of Imported vs Generic Medications: India manufactures high-quality generic versions of many cancer drugs. Choosing generics over imported brands can reduce treatment costs by 30–50% without affecting efficacy.
  • Supportive Services and Diagnostics: Routine imaging (PET-CT, MRI), blood tests, and infection control measures can add to the overall cost. Nutritional support, psychological counseling, and rehabilitation may also be factored into advanced cancer care.
  • Post-Treatment Monitoring and Follow-Up: Even after the initial treatment is complete, patients require regular check-ups, laboratory tests, and scans to monitor for recurrence or late effects. These ongoing costs should be factored into a long-term care budget.

Why Choose India for Non-Hodgkin's Lymphoma Treatment?

India is a leading destination for international cancer patients seeking affordable, evidence-based, and technologically advanced care. When it comes to treating Non-Hodgkin lymphoma, the country offers several unique advantages:

  • Cost-Effective Treatment Without Compromising Quality: India provides access to top-tier cancer care (including chemotherapy, immunotherapy, stem cell transplant, and even CAR T-cell therapy) at 70–90% lower costs than the US, UK, or UAE.
  • Globally Trained Oncologists and Hematologists: Many Indian cancer specialists are trained at leading international institutions, bringing decades of experience in treating blood cancers, including complex and relapsed cases.
  • Availability of Advanced Therapies: From the latest PET-CT imaging to bone marrow transplants and monoclonal antibody therapy, Indian hospitals adhere to international guidelines (NCCN, ESMO) and offer access to cutting-edge treatments, including CAR T-cell therapy.
  • Full-Service International Patient Support: Most leading hospitals have dedicated international patient departments that provide:
    • Help with medical visa processing
    • Airport pickup and drop-off
    • Language interpreters (Arabic, Swahili, French, etc.)
    • Assistance with accommodation and dietary preferences
    • Post-treatment teleconsultations
  • No Waiting Lists: Unlike some Western countries, patients in India can begin treatment almost immediately after diagnosis. It is crucial for aggressive forms of lymphoma, where early intervention can significantly improve outcomes.
  • High Success Rates and Patient Satisfaction: Through standardized protocols and continuous quality monitoring, Indian hospitals consistently achieve excellent treatment outcomes in both adult and pediatric lymphoma cases.

Patient Testimonial

Fatima D., Kenya

"When I was diagnosed with Burkitt Lymphoma, my family and I were devastated. The treatment options in Nairobi were limited and extremely expensive. We found Fortis Hospital in Gurgaon and connected with Dr. Rahul Bhargava through a patient referral. The team was incredibly supportive from the beginning, helping with visas, airport pickup, and accommodations. I underwent six cycles of R-CHOP chemotherapy followed by a short course of radiation. Today, I'm cancer-free and back to living my life. The care I received in India was not just affordable, but it was world-class."

Reza M., Iran

"As a 43-year-old engineer, my life took a turn when I was diagnosed with stage III non-Hodgkin lymphoma. I couldn't afford treatment in Europe and feared losing time. A friend suggested India. I researched and chose a leading hospital in Delhi. The doctors were transparent, knowledgeable, and kind. My chemotherapy cycles went smoothly, and the nurses took great care of me. Language wasn't a problem as they arranged a translator. I'm now in remission and forever grateful for the second chance India gave me."

Frequently Asked Questions

Yes, many types of non-Hodgkin lymphoma are curable, especially when detected early. Aggressive lymphomas often respond well to chemotherapy and immunotherapy, and some patients achieve long-term remission or complete cure.

The success rate for non-Hodgkin's lymphoma treatment in India ranges from 60% to 90%, depending on the type of lymphoma, stage at diagnosis, and overall patient health. Indolent forms may have a chronic course but are manageable for many years with proper care.

Most chemotherapy regimens last 3 to 6 months. In cases requiring a stem cell transplant, treatment duration may extend to 6–9 months, including preparation and recovery time. Regular follow-ups are essential after treatment.

Doctors usually recommend staying in India for 2–4 weeks post-treatment to monitor recovery and manage any side effects. In the case of transplants, patients may need to stay longer for immune recovery.

Yes, many hospitals treating non-Hodgkin's lymphoma in India are NABH (National Accreditation Board for Hospitals) and JCI (Joint Commission International) accredited, ensuring global standards in care.

Absolutely. Indian hospitals provide teleconsultation services for post-treatment follow-up, ensuring continuity of care after you return home.

Yes, cancer hospitals in India welcome caregivers and even provide accommodation and meal support for them within or near the hospital premises.

Most hospitals offer multilingual support, including interpreters for Arabic, French, Swahili, Russian, and other languages, to help international patients communicate effectively with healthcare professionals.

Some international insurance providers do cover treatment abroad. Patients should consult with their insurance companies and the hospital's international patient team to obtain pre-approval and coordinate billing.

Send a query